CO6140022A2 - Uso de una matriz hidrofila que comprende un derivado de acido poliacrilico un eter de celulosa y un desintegrante para la fabricacion de un medicamento para tratar trastornos genitales femeninos - Google Patents

Uso de una matriz hidrofila que comprende un derivado de acido poliacrilico un eter de celulosa y un desintegrante para la fabricacion de un medicamento para tratar trastornos genitales femeninos

Info

Publication number
CO6140022A2
CO6140022A2 CO08136879A CO08136879A CO6140022A2 CO 6140022 A2 CO6140022 A2 CO 6140022A2 CO 08136879 A CO08136879 A CO 08136879A CO 08136879 A CO08136879 A CO 08136879A CO 6140022 A2 CO6140022 A2 CO 6140022A2
Authority
CO
Colombia
Prior art keywords
polyacrylic acid
amounts
acid derivative
hydrophilic matrix
disintegrant
Prior art date
Application number
CO08136879A
Other languages
English (en)
Inventor
Luigi Bruschi Stefano De
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of CO6140022A2 publication Critical patent/CO6140022A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Una matriz hidrófila para la fabricación de una formulación para el tratamiento de trastornos genitales femeninos, que comprende: a) por lo menos un derivado de ácido poliacrílico en cantidades de 0.5-40% con respecto al peso de la matriz; b) por lo menos un éter de celulosa; y c) por lo menos un desintegrante; y por lo menos un principio activo farmacéuticamente aceptable, en donde dicho(s) desintegrante(s) se selecciona de celulosas modificadas tales como carboximetilcelulosa de sodio reticulada, povidona reticulada, tal como crospovidona, almidones naturales tal como almidón de maíz, almidón de papa, almidones directamente comprensibles, almidones modificados tales como carboximetilalmidones y glicolato de almidón de sodio, derivados de almidones tales como amilasa, ácido algínico y alginato de sodio, celulosa microcristalina. 2.- Una matriz hidrófila de acuerdo con la reivindicación 1, caracterizado porque dicho(s) desintegrante(s) es(son) carboximetilcelulosa de sodio reticulada. 3.- Una matriz hidrófila de acuerdo con la reivindicación 1, caracterizado porque dicho(s) derivado(s) de ácido poliacrílico está(n) presente(s) en cantidades de 2-40%, preferiblemente de 2-30%; dicho éter(es) de celulosa en cantidades de 30-90% y dicho(s) desintegrante(s) en cantidades de 2-50%, con respecto al peso de la matriz. 4.- Una matriz hidrófila de acuerdo con la reivindicación 1, caracterizado porque dicho(s) derivado(s) de ácido poliacrílico está(n) presente(s) en cantidades de 1-20%, dicho(s) éter(es) de celulosa en cantidades de 40- 80% y dicho(s) desintegrante(s) en cantidades de 5-40%, con respecto al peso de la matriz. 5.- Una matriz hidrófila de acuerdo con la reivindicación 1, caracterizado porque dicho(s) derivado(s) de ácido poliacrílico es(son) un ácido poliacrílico reticulado con éteres polialquenilo de azúcares o polialcoholes, preferiblemente carbómero. 6.- Una matriz hidrófila de acuerdo con la reivindicación 1, caracterizado porque dicho(s) derivado(s) de ácido poliacrílico es(son) un ácido poliacrílico reticulado con divinilgloicol, preferiblemente, policarbofilo. 7.- Una matriz hidrófila de acuerdo con la reivindicación 1, caracterizado porque dicho(s) éter(es) de celulosa se selecciona(n) de hidroxialquilcelulosa, alquilcelulosa, carboximetilcelulosa o su sal.
CO08136879A 2006-06-29 2008-12-24 Uso de una matriz hidrofila que comprende un derivado de acido poliacrilico un eter de celulosa y un desintegrante para la fabricacion de un medicamento para tratar trastornos genitales femeninos CO6140022A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06116269A EP1872775A1 (en) 2006-06-29 2006-06-29 Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders

Publications (1)

Publication Number Publication Date
CO6140022A2 true CO6140022A2 (es) 2010-03-19

Family

ID=37433668

Family Applications (1)

Application Number Title Priority Date Filing Date
CO08136879A CO6140022A2 (es) 2006-06-29 2008-12-24 Uso de una matriz hidrofila que comprende un derivado de acido poliacrilico un eter de celulosa y un desintegrante para la fabricacion de un medicamento para tratar trastornos genitales femeninos

Country Status (25)

Country Link
US (1) US8865201B2 (es)
EP (2) EP1872775A1 (es)
JP (1) JP5205374B2 (es)
KR (1) KR101443149B1 (es)
CN (2) CN101478951A (es)
AR (1) AR061771A1 (es)
AT (1) ATE455534T1 (es)
BR (1) BRPI0713298A2 (es)
CA (1) CA2652226C (es)
CO (1) CO6140022A2 (es)
CY (1) CY1109910T1 (es)
DE (1) DE602007004486D1 (es)
DK (1) DK2032123T3 (es)
EA (1) EA018257B1 (es)
ES (1) ES2339069T3 (es)
HK (1) HK1128587A1 (es)
HR (1) HRP20100159T1 (es)
MA (1) MA30597B1 (es)
MX (1) MX2008016508A (es)
NO (1) NO20090095L (es)
PL (1) PL2032123T3 (es)
PT (1) PT2032123E (es)
RS (1) RS51279B (es)
SI (1) SI2032123T1 (es)
WO (1) WO2008000683A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
EP2163240A1 (en) * 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova A method for the production of bioadhesive compact matrices
EP2344121B1 (en) * 2008-10-23 2017-07-12 Henkel IP & Holding GmbH Vaginal pellets comprising debranched starch
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
EP2243482A1 (en) * 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
BR112016009008B8 (pt) * 2013-10-22 2023-01-31 Therapeuticsmd Inc Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
CN105796520A (zh) * 2014-12-29 2016-07-27 四川滇虹医药开发有限公司 一种缓释型硝酸布康唑直压片剂及其制备方法
WO2016115639A1 (en) 2015-01-23 2016-07-28 Biocidium Biopharmaceuticals Inc. Anti-bacterial compositions
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11026883B2 (en) * 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
GB201808567D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
CN109010320B (zh) * 2018-09-18 2021-09-14 浙江汇能生物股份有限公司 一种双释型聚卡波非钙颗粒剂及制备方法和畜禽中的应用
CN114129530A (zh) * 2021-12-08 2022-03-04 南京康川济医药科技有限公司 一种黄体酮缓释组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2232438A (en) 1934-08-04 1941-02-18 Schering Corp Unsaturated pregnanolones and pregnandiones and a method of producing the same
US2243887A (en) 1935-11-09 1941-06-03 Schering Corp Tertiary carbinols of the cyclopentano-polyhydrophenanthrene series and a method of producing the same
US2251939A (en) 1935-11-22 1941-08-12 Schering Corp Tertiary alcohols of the cyclopentano polyhydro phenanthrene series and a method of producing the same
US2379832A (en) 1936-06-02 1945-07-03 Schering Corp Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
US2265976A (en) 1937-10-25 1941-12-09 Schering Corp Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
US2314185A (en) 1939-09-01 1943-03-16 Zondek Bernhard Process for the manufacture of progesterone
BE665514A (es) 1964-06-16
NL146838B (nl) 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
HUP0301465A3 (en) 2000-06-23 2006-07-28 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
FR2813865B1 (fr) 2000-09-08 2002-12-20 Rexam Sofab Dispositif a buse unique pour la distribution selective de deux produits
CA2422424C (en) 2000-09-19 2009-12-01 Cima Labs, Inc. Pharmaceutical compositions for rectal and vaginal administration
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
CN1302764C (zh) 2005-01-10 2007-03-07 凌沛学 一种妇科用药阴道凝胶片

Also Published As

Publication number Publication date
MX2008016508A (es) 2009-04-22
DE602007004486D1 (de) 2010-03-11
SI2032123T1 (sl) 2010-04-30
PL2032123T3 (pl) 2010-06-30
CN101478951A (zh) 2009-07-08
EP1872775A1 (en) 2008-01-02
EA018257B1 (ru) 2013-06-28
WO2008000683A1 (en) 2008-01-03
KR20090033341A (ko) 2009-04-02
EP2032123A1 (en) 2009-03-11
AR061771A1 (es) 2008-09-17
PT2032123E (pt) 2010-04-07
JP2009541419A (ja) 2009-11-26
ES2339069T3 (es) 2010-05-14
CY1109910T1 (el) 2014-09-10
KR101443149B1 (ko) 2014-09-23
CA2652226A1 (en) 2008-01-03
CN103071157A (zh) 2013-05-01
HRP20100159T1 (hr) 2010-05-31
EA200900087A1 (ru) 2009-06-30
NO20090095L (no) 2009-01-07
CA2652226C (en) 2014-08-12
ATE455534T1 (de) 2010-02-15
JP5205374B2 (ja) 2013-06-05
DK2032123T3 (da) 2010-03-08
US20110091555A1 (en) 2011-04-21
BRPI0713298A2 (pt) 2012-04-17
MA30597B1 (fr) 2009-07-01
US8865201B2 (en) 2014-10-21
RS51279B (sr) 2010-12-31
HK1128587A1 (en) 2009-10-30
EP2032123B1 (en) 2010-01-20

Similar Documents

Publication Publication Date Title
CO6140022A2 (es) Uso de una matriz hidrofila que comprende un derivado de acido poliacrilico un eter de celulosa y un desintegrante para la fabricacion de un medicamento para tratar trastornos genitales femeninos
AU2014363599B2 (en) Orally disintegrating solid dosage unit containing an estetrol component
JP2010047612A5 (es)
NZ592719A (en) PHARMACEUTICAL FORMULATION 514 comprising 4-[3-( 4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
NZ611467A (en) Rapidly dispersing granules, orally disintegrating tablets and methods
JP2009541419A5 (es)
JP2011157401A5 (es)
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
MX2009011554A (es) Preparacion solida estable conteniendo un derivado de 4,5-epoximorfinano.
EP2210591A3 (en) Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
MX2011005633A (es) Formas de dosificacion solida de bendamustina.
SG194725A1 (en) Rapid dissolve tablet compositions for vaginal administration
RU2013106172A (ru) Композиция для снятия усталости, состав и их применение
CN103655503A (zh) 一种米拉贝隆缓释片及其制备方法
RU2010101797A (ru) Фармацевтический твердый препарат, содержащий бензазепины и способ его получения
CR10668A (es) Comprimidos pediatricos de capecitabina
AR061790A1 (es) Composicion farmaceutica solida para la administracion oral, formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina, y su uso en la manufactura de un medicamento
PE20061390A1 (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
RU2006137329A (ru) Распадающиеся таблетки, содержащие ликарбазепин
ATE451097T1 (de) Valsartanformulierungen
CN106214653A (zh) 一种沙芬酰胺缓释片及其制备方法
CN102341104A (zh) 含有甲磺酸雷沙吉兰的药物组合物
CN105769883A (zh) 一种复方磺胺甲噁唑分散片及其制备方法
WO2019013583A3 (ko) 약제학적 제제 및 그 제조방법
EA200900249A1 (ru) Фармацевтическая композиция и способ ее получения